Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression.

Journal of lipid research - 1 Sept 2013

Parker Rex A, Garcia Ricardo, Ryan Carol S, Liu Xiaoqin, Shipkova Petia, Livanov Valentin, Patel Pritesh, Ho Siew P

Abstract excerpt

Proprotein convertase subtilisin-kexin-9 (PCSK9) inhibition markedly augments the LDL lowering action of statins. The combination is being evaluated for long-term effects on atherosclerotic disease outcomes. However, effects of combined treatment on hepatic cholesterol and bile acid metabolism ha...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Acids and Salts
Share to Cholesterol
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Proprotein Convertase 9

Share to Proprotein Convertases

Share to Protease Inhibitors

Share to Serine Endopeptidases

Source

Open in PubMed Open full text

Identifiers

PMID: 23614904
DOI: 10.1194/jlr.M038331
PMCID: PMC3735938

Genes

PCSK9

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23614904-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression.PMID 23614904Read ↗

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read ↗

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.Semantic proximity Read ↗

Targeting PCSK9 for the treatment of hypercholesterolemia.Semantic proximity Read ↗

PCSK9 Inhibitors: Pharmacology and Therapeutic PotentialSemantic proximity Read ↗

Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency.Semantic proximity Read ↗

Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages.Semantic proximity Read ↗

Aaptamine Counteracts Statin-Induced PCSK9 Elevation to Improve LDL Receptor Expression and Cholesterol UptakeSemantic proximity Read ↗

Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expressionSemantic proximity Read ↗

Of mice and men: murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism.Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells.Semantic proximity Read ↗

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.